Hologic Continues 2021 Spending Spree With $795M Acquisition Of Mobidiag

Mobidiag develops molecular diagnostic tests and instrumentation that will expand Hologic’s acute care testing capabilities.

Antibiotic-resistant-bacteria
• Source: shutterstock.com

Hologic plans to acquire Finland-based molecular diagnostic company Mobidiag for $785m to take advantage of the fast-growing acute care market.

Mobidiag develops and markets polymerase chain reaction (PCR) tests for acute conditions, including gastrointestinal and respiratory infections, as well as antimicrobial resistance. The company’s Novodiag platform combines real-time PCR and...

More from Deals

More from Business